drugset / Trial / NCT00765674

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674

Phase 3 Completed 1191 enrolled Novartis
RandomizedParallel-groupTriple-blindTreatment

Summary

This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.

Timeline

Start
2008-09
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg Oral
Subject Amlodipine Other / unclassified 10 mg Oral
Subject Hydrochlorothiazide Unknown 25 mg Oral

Indications